Skip to main content

ORIGINAL RESEARCH article

Front. Drug Deliv.
Sec. Oral Drug Delivery
Volume 4 - 2024 | doi: 10.3389/fddev.2024.1456654
This article is part of the Research Topic Oral Delivery of Peptides and Proteins View all 3 articles

Glucagon-like Peptide-1 Receptor Agonists for Treatment of Diabetes and Obesity: Advantage of Oral Delivery

Provisionally accepted
Roger R. New Roger R. New 1,2*R R. New R R. New 3*M Bogus M Bogus 2*G N. Travers G N. Travers 2*U Hahn U Hahn 4*A Klein A Klein 4*Michael Burnet Michael Burnet 4J H. Wang J H. Wang 5*Hao Wen Hao Wen 5
  • 1 Proxima Concepts Ltd, London, United Kingdom
  • 2 Diabetology Ltd, London, United Kingdom
  • 3 Middlesex University, London, United Kingdom
  • 4 Synovo GmbH, Tubingen, Germany
  • 5 Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Region, China

The final, formatted version of the article will be published soon.

    GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions which can deliver these peptides efficiently without requiring use of excessively high doses. This paper describes the ability of an oral peptide delivery formulation, Axcess™, to enhance uptake of GLP-1 receptor agonists via the intestine, resulting in changes in insulin and glucose blood levels indicative of biopotencies of 9% for exendin-4 and 14.8% for semaglutide in preclinical models. The route of delivery suggests that the peptides will be able to interact with the GLP-1 receptors on the vagal afferents of the intestine, as is the case for native GLP-1 in healthy individuals. GLP-1 receptor agonists administered via this route will be a valuable addition to the therapeutic modalities available for treatment of diabetes and obesity.

    Keywords: GLP-1, oral delivery, vagal afferents, diabetes, Obesity, peptide

    Received: 28 Jun 2024; Accepted: 14 Oct 2024.

    Copyright: © 2024 New, New, Bogus, Travers, Hahn, Klein, Burnet, Wang and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Roger R. New, Proxima Concepts Ltd, London, United Kingdom
    R R. New, Middlesex University, London, NW4 4BT, United Kingdom
    M Bogus, Diabetology Ltd, London, United Kingdom
    G N. Travers, Diabetology Ltd, London, United Kingdom
    U Hahn, Synovo GmbH, Tubingen, Germany
    A Klein, Synovo GmbH, Tubingen, Germany
    J H. Wang, Xinjiang Medical University, Ürümqi, Xinjiang Uyghur Region, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.